Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024442
Filing Date
2022-11-10
Accepted
2022-11-10 16:04:57
Documents
75
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rani-20220930.htm   iXBRL 10-Q 3575060
2 EX-31.1 rani-ex31_1.htm EX-31.1 19703
3 EX-31.2 rani-ex31_2.htm EX-31.2 19749
4 EX-32.1 rani-ex32_1.htm EX-32.1 13678
  Complete submission text file 0000950170-22-024442.txt   11893403

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rani-20220930_cal.xml EX-101.CAL 47618
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rani-20220930_def.xml EX-101.DEF 364921
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rani-20220930_lab.xml EX-101.LAB 596194
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rani-20220930.xsd EX-101.SCH 71238
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rani-20220930_pre.xml EX-101.PRE 479767
69 EXTRACTED XBRL INSTANCE DOCUMENT rani-20220930_htm.xml XML 2196514
Mailing Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131
Business Address 2051 RINGWOOD AVENUE SAN JOSE CA 95131 (408) 457-3700
Rani Therapeutics Holdings, Inc. (Filer) CIK: 0001856725 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40672 | Film No.: 221377004
SIC: 2834 Pharmaceutical Preparations